From the call today Operator We do have a question now from Dipesh Patel from H.C. Wainwright.
Dipesh Patel Thank you. Hi, James. Thanks for the update. How would you anticipate the company to compete or fare against other cancer diagnostic tests? And what differentiators might be worth noting that specific to StageZero?
James Howard-Tripp That's a super question. Thank you, Dipesh, and thanks for joining the call. We're actually doing extremely well on that. We have a number of competitors out there, always stack up against them, so we can get real, real market feedback, real-time feedback. We're actually beginning to take contracts from some of the other guys. And the reason is really are the following. The other technologies tend to – are even limited. In other words, they do just one or two cancers in terms of where it is. So most – most don't do the breast. But when you do the breast, when you do the multiple cancer aspect, the other technologies are typically fairly good at finding late-stage cancer, but not very good at finding early-stage cancer. If we look at circulating tumor cells, for example, it's obvious that with very small tumors, very early-stage tumors, there's less CTC in the blood, it makes it a little more difficult to find in addition to that, if they're relying on methylation markers, the methylation markers typically increase with stage of cancer. In other words, they take time to accumulate – so it's just much easier to find later-stage cancers. So where we're finding people actually speak with us or come to us and ask if they can switch programs, for example, it is because either there are not seeing the kind of results, they totally expect to find or notably, they're not seeing the early stage cancers. And so I think that's a huge advantage for us.